Literature DB >> 10720287

Mild familial neurofibromatosis 2 associates with expression of merlin with altered COOH-terminus.

M Sainio1, J Jääskeläinen, H Pihlaja, O Carpén.   

Abstract

OBJECTIVE: To understand molecular details of the pathogenesis of a very mild and homogenous form of neurofibromatosis 2 (NF2).
BACKGROUND: Inactivation of the NF2 tumor suppressor gene leads to the development of multiple nervous system tumors, accompanied by loss of the NF2 gene product, merlin, or schwannomin. The severity of disease varies between patients, and the biologic basis of this variation is poorly understood.
METHODS: We studied the genotype-phenotype correlation in a large pedigree with extremely mild and uniform disease manifesting as slowly growing bilateral vestibular nerve schwannomas of late onset.
RESULTS: The tumors demonstrated a low proliferation rate and loss of the wild-type NF2 allele. The disease is caused by a novel mutation in the NF2 gene at intron 15 splice donor site (1737 + 3 a --> t), which was identified in all carriers by the minisequencing method. The mutation resulted in splicing out of exon 15 and production of two transcripts: a novel mutant transcript with exon 16 and overexpression of isoform III, normally detected at a low level. Both transcripts encode for the COOH-terminus of isoform III. Immunoblotting of patient fibroblasts and tumor tissue demonstrated variant merlin with altered COOH-terminus.
CONCLUSIONS: The mutational skip of exon 15 and the expression of a protein with the COOH-terminus of isoform III correlates with the exceptionally mild NF2, and suggests tumor suppressor activity for isoform III. The detection of expressed mutant proteins may provide useful information for prediction of the clinical outcome of individual mutations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720287     DOI: 10.1212/wnl.54.5.1132

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  9 in total

Review 1.  The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.

Authors:  M E Baser; L Kuramoto; R Woods; H Joe; J M Friedman; A J Wallace; R T Ramsden; S Olschwang; E Bijlsma; M Kalamarides; L Papi; R Kato; J Carroll; C Lázaro; F Joncourt; D M Parry; G A Rouleau; D G R Evans
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

2.  Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas.

Authors:  K D Geiger; P Stoldt; W Schlote; A Derouiche
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  A deletion causing NF2 exon 9 skipping is associated with familial autosomal dominant intramedullary ependymoma.

Authors:  Ilyess Zemmoura; Patrick Vourc'h; Agathe Paubel; Béatrice Parfait; Joëlle Cohen; Frédéric Bilan; Alain Kitzis; Cécilia Rousselot; Fabrice Parker; Patrick François; Christian R Andres
Journal:  Neuro Oncol       Date:  2013-12-18       Impact factor: 12.300

Review 4.  Neurofibromatosis-2 and spinal cord ependymomas: Report of two cases and review of the literature.

Authors:  Dolly G Aguilera; Claire Mazewski; Matthew J Schniederjan; Traci Leong; William Boydston; Tobey J Macdonald
Journal:  Childs Nerv Syst       Date:  2010-12-04       Impact factor: 1.475

5.  A novel alternative splicing isoform of NF2 identified in human Schwann cells.

Authors:  Fang Su; Zhengguang Zhou; Wen Su; Zishu Wang; Qiong Wu
Journal:  Oncol Lett       Date:  2016-06-08       Impact factor: 2.967

6.  Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.

Authors:  Marianne F James; Johanna M Lelke; Mia Maccollin; Scott R Plotkin; Anat O Stemmer-Rachamimov; Vijaya Ramesh; James F Gusella
Journal:  Neurobiol Dis       Date:  2007-09-19       Impact factor: 5.996

7.  Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.

Authors:  Pierig Lepont; John T Stickney; Lauren A Foster; Jin-Jun Meng; Robert F Hennigan; Wallace Ip
Journal:  Mutat Res       Date:  2007-08-06       Impact factor: 2.433

8.  Distinct overlapping sequences at the carboxy-terminus of merlin regulate its tumour suppressor and morphogenic activity.

Authors:  Minja Laulajainen; Maria Melikova; Taru Muranen; Olli Carpén; Mikaela Grönholm
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

9.  Genetic Severity Score predicts clinical phenotype in NF2.

Authors:  Dorothy Halliday; Beatrice Emmanouil; Pieter Pretorius; Samuel MacKeith; Sally Painter; Helen Tomkins; D Gareth Evans; Allyson Parry
Journal:  J Med Genet       Date:  2017-08-28       Impact factor: 6.318

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.